Dudediligence.

Aktis Oncology, Inc

AKTSNASDAQ · Pharmaceutical Preparations
Write an idea

Insiders

Last 12 months

Sales planned on beside the trades reported on , and whether each names a .

Planned ·

$3,525,543

5 notices · 132,921 sh

Oct 2025 to Oct 2026

Reported ·

$114.3M

0 sales · 9 buys

Oct 2025 to Jun 2026

The two figures cover different periods.

PLANNED · FORM 144Oct 2025 to Oct 2026REPORTED · FORM 4Oct 2025 to Jun 2026N2025DJ2026FMAMJJASO2026-09-23: Akos Czibere, Form 1442026-07-20: KEN HERRMANN, Form 1442026-07-17: KEN HERRMANN, Form 1442026-07-08: AKOS CZIBERE, Form 1442026-07-08: SHULAMIT RON-BIGGER, Form 1442026-01-12: NODELMAN OLEG, bought2026-01-12: Kim Helen Susan, bought2026-01-12: Vida Ventures II, LLC, bought2026-01-12: GADICKE ANSBERT, bought2026-01-12: EVNIN LUKE, bought2026-01-12: Foley Todd, bought
under a no plan named▼ sale▲ buysize is dollars

Form 144 notices, newest first

2026-09-23Akos Czibere, Chief Medical Officer$552,750
25,000 shplan 2026-06-24Form 4s on file end Jun 23144 ↗
2026-07-20KEN HERRMANN, Director$119,275
4,856 shno plan dateForm 4s on file end Jun 23144 ↗
2026-07-17KEN HERRMANN, Director$77,259
3,065 shno plan dateForm 4s on file end Jun 23144 ↗
2026-07-08AKOS CZIBERE, Chief Medical Officer$1,388,700
50,000 shplan 2026-06-24Form 4s on file end Jun 23144 ↗
2026-07-08SHULAMIT RON-BIGGER, Chief Operating Officer$1,387,560
50,000 shno plan dateForm 4s on file end Jun 23144 ↗